Tirzepatide is a peptide medicine designed to act simultaneously on two of the body's most important metabolic hormones. It is the active ingredient in Mounjaro, the brand name under which Eli Lilly markets the medication, and it is the molecule responsible for the trial results that have made it one of the most studied medications in modern endocrinology.

The basics are these. It is a 39 amino acid peptide, synthesised in laboratories, designed to mimic and amplify the body's natural response to food. It is given once weekly by injection under the skin. In South Africa, where it has been available since December 2024, it is sold as a pre-filled multi-dose KwikPen device, distributed by Aspen Pharmacare under licence from Eli Lilly. It is registered with SAHPRA for two indications: type 2 diabetes (since December 2024) and chronic weight management (since October 2025).

Tirzepatide produces the largest mean weight reductions of any pharmaceutical treatment ever brought to market for obesity. SURMOUNT-1 Trial Outcomes

What It Actually Does

To understand tirzepatide, it helps to understand what your gut does when you eat. The intestines release a set of signalling molecules called incretins. The most studied is GLP-1 (glucagon-like peptide-1). A close second is GIP (glucose-dependent insulinotropic polypeptide). Both are released within minutes of eating. Both tell the pancreas to release insulin, slow gastric emptying, and quiet appetite signalling in the brain.

Older medications such as semaglutide (sold as Ozempic and Wegovy) act on the GLP-1 receptor only. Tirzepatide acts on both. This is the central pharmacological fact about the molecule, and it explains both why it works the way it does and why the trial results have been stronger than the medications that preceded it.

The dual action produces:

The combined effect is what produces the average 20 percent body weight reduction at maximum dose seen in the SURMOUNT-1 trial in adults with obesity, and the average HbA1c reductions of around 2 percentage points seen in the SURPASS diabetes programme.

Where It Came From

Eli Lilly developed tirzepatide internally as part of a broader programme exploring multi-receptor incretin therapy. The hypothesis was straightforward in principle: if GLP-1 alone produced clinically useful results, would adding GIP activity produce stronger results, or would the second pathway introduce side effects that cancelled out the benefit?

The Phase 1 trials began in 2017. The SURPASS programme for type 2 diabetes ran from 2019. The SURMOUNT programme for obesity began in 2020. By 2022 the medication had been approved by the United States Food and Drug Administration for type 2 diabetes. Approval for weight management followed in 2023 under the brand name Zepbound. Other major regulators followed, with SAHPRA approving the diabetes indication in December 2024 and the weight management indication in October 2025.

Note On Brand Names Eli Lilly markets the molecule as Mounjaro for type 2 diabetes globally. In the United States, the weight management indication uses the brand Zepbound. In South Africa, both indications use the Mounjaro brand because Aspen distributes a single KwikPen across both uses.

How It Is Given

Tirzepatide is administered as a once weekly subcutaneous injection. Under the skin, into the fatty tissue of the abdomen, the front of the thigh, or the back of the upper arm. The KwikPen device used in South Africa is a multi-dose pen with the dose pre-measured for each injection.

Six dose strengths exist: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The starting dose for all patients is 2.5 mg weekly, well below the therapeutic dose, with increases every four weeks. The full titration to the maximum 15 mg takes around five months. A detailed view of the dose schedule lives here.

The Half Life Question

For a once weekly injection to work, the medication must persist in the bloodstream for the full week. Most peptides, including natural GIP and GLP-1, are cleared within minutes. The body has enzymes specifically designed to break them down.

Tirzepatide solves this problem with a chemical modification. A fatty acid chain has been attached to the peptide backbone, allowing the molecule to bind reversibly to albumin, the most abundant protein in blood. While bound to albumin, the molecule is protected from enzymatic breakdown. The half life is approximately five days, which means a single weekly injection produces continuous receptor activation across the full week.

This has practical consequences. Missing one dose is forgiving because the previous dose is still partly active. Stopping the medication is gradual because levels decline over weeks rather than days. Switching doses is smooth because the previous and new dose levels overlap during the transition.

If You Are Considering Mounjaro

An online consultation reviews your medical history and determines whether tirzepatide is appropriate.

Start Consultation

What The Molecule Cannot Do

Tirzepatide is not a metabolic stimulant. It does not directly increase calorie burn. It does not target body fat specifically. It does not reverse the underlying drivers of obesity or diabetes. What it does is reduce appetite and improve the body's hormonal response to food. The downstream effect is reduced calorie intake and improved glucose handling, which translates over months into weight reduction and improved metabolic markers.

This matters for two reasons. First, the medication works best alongside the lifestyle adjustments it was studied with: reduced calorie diet, increased physical activity, and adequate protein and movement to protect lean mass during weight loss. Second, the effect persists only while the medication is in your system. Stopping leads to gradual return of appetite and weight regain over the following year, as the SURMOUNT-4 trial documented in detail.

The South African Picture

By mid-2026, tirzepatide had reshaped the South African prescription market. Aspen Pharmacare reported in early 2026 that Mounjaro had become the country's highest selling pharmaceutical product, achieving that status in November 2025 according to IQVIA sales data. By the end of January 2026, Mounjaro held 52 percent of the SA GLP-1 market by value. Expected sales for the year through June 2026 exceeded R1.3 billion.

For most South Africans considering it, the practical questions are clinical and economic. Whether tirzepatide is appropriate for their specific condition. Whether it can be afforded long term. Whether the trial results translate to their individual situation. These are questions a consultation with a registered SA doctor is designed to address. The consultation process is described here.

Related Reading

Frequently Asked

None pharmaceutically. Tirzepatide is the active ingredient. Mounjaro is the brand name Eli Lilly uses for the medication. In the United States, the same molecule is also sold as Zepbound specifically for weight management. In South Africa, both indications use the Mounjaro brand.

Yes. Tirzepatide is a 39 amino acid synthetic peptide engineered to bind to two receptors at once. The body cannot absorb peptides through the gut, which is why it is given by injection rather than tablet.

The molecule has been engineered with a fatty acid chain that allows it to bind to albumin in the bloodstream, slowing its clearance. Half life is approximately five days, which makes weekly dosing both possible and practical.

The clinical trial programmes (SURPASS for diabetes, SURMOUNT for weight management) included diverse global populations. Real world South African data has accumulated since the December 2024 launch and continues to track international experience.